Insulin Innovation: Celebrating 100 years and beyond - Industry Symposium Supported by Novo Nordisk

Session description - This symposium will celebrate a century of insulin by reflecting on 100 years of innovation and looking into the future of insulin therapies. The aims for the symposium are to highlight the major advances in insulin innovation over the past century, the remaining challenges, and the future landscape of potential insulin therapies. World-renowned diabetes experts will take attendees on a voyage beginning with the history of the discovery and development of insulin and the early days of insulin research. They will guide the audience through the latest clinical evidence supporting the use of once-weekly basal insulin in diabetes. Finally, they will transport the audience into the future with an exciting preview of the prospective landscape of insulin and other therapies for diabetes. There will be opportunities for attendees to engage directly through polling questions and to ask questions throughout the session, which will be answered during a live panel discussion.

MiniMed™ 780G System: Improving Clinical Outcomes while Reducing Diabetes Management Burden - Industry Symposium Supported by Medtronic International Trading Sàrl

Session description - Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved both clinical and patient related outcomes. In this symposium, the most recent data on the transformation brought by the introduction of automated insulin delivery system - the MiniMed™ 780G system-, on goals obtainment in real world will be presented. The opportunities brought by these to onboard a wider population of people with diabetes, even those without extensive exposure to technology, will be demonstrated. Further innovation toward extending infusion sets wear to 7 days, and its performance with automated insulin delivery system will be presented, as an additional step toward improving users’ experience. A look toward the future innovation will be offered by the leaders of Medtronic R&D

Introducing Tempo: A Connected Insulin Pen to Simplify Diabetes Management - Industry Symposium Supported by Eli Lilly

Session description - This symposium will introduce Tempo™, a Personalized Diabetes Management System from Eli Lilly, that integrates insulin dosing data with technology to help simplify diabetes management.   Digital health technologies can help improve patient data visibility, physician-patient collaboration, clinical decision-making, and patient self-management, ultimately leading to better outcomes.   Faculty will discuss the complexities of insulin management, and how insulin dosing data may help facilitate communication between you and the people you treat.  Automating insulin dosing data may help:  

• Gain an understanding of their management patterns

• Stay informed between office visits

• Feel empowered to engage in shared decision-making

The Tempo Smart Button™ (pending CE mark) attaches to a Tempo Pen™ prefilled with Abasaglar, Humalog, or Lyumjev insulin.  Data from the Tempo System will integrate with commercially available software. The Tempo Smart Button is intended to reliably store and transmit insulin dosing data to a compatible app.  Tempo provides a comprehensive view of how people manage their insulin day-to-day.  Adding insulin dosing data to other data related to your patients’ insulin therapy (e.g., blood glucose, carbohydrate intake) may help inform treatment decisions. This program is for all healthcare professionals treating people with diabetes on multiple daily injections of mealtime insulin.

The materials for Tempo Pen™ contained in this virtual symposium are approved for use only in EU and UK. The Tempo Smart Button™ is pending CE mark. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).